Navigation Links
DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
Date:10/28/2009

WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

"The achievement of this milestone signifies that dermatologists in the U.S. and abroad continue to embrace Levulan PDT for Grade 1 and 2 actinic keratoses (AKs) of the face and scalp and the beneficial outcomes it offers their patients," said Bob Doman, DUSA's President and Chief Executive Officer.

"We believe that Levulan PDT is one of the fastest growing office based procedures in dermatology today, having achieved a 39% compounded annual growth rate in worldwide Kerastick revenues over the past four years," continued Doman.

"PDT is an important, versatile technology that should be integrated more frequently in clinical dermatology practice," said Jill Waibel, M.D., a dermatologist in private practice at Palm Beach Esthetic Dermatology & Laser Center, West Palm Beach, Florida.

"We are excited to have reached the one million Kerastick sales milestone, and believe that significant growth potential exists for Levulan PDT in the treatment of AKs and other potential indications," Doman concluded.

DUSA continues to explore other potential indications for the utilization of Levulan PDT for the treatment of various skin conditions and has initiated a pilot study on Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. ® is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

Forward Looking Statements

Except for historical information, this news release contains certain forward-looking statements that represent our current expectations and beliefs concerning future events, and involve certain known and unknown risk and uncertainties. These forward-looking statements relate to belief concerning the speed of Levulan growth and its potential for additional growth and additional indications. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, actions by health regulatory authorities, sufficiency of funds, the regulatory approval process, results of clinical trials, reliance on third party manufacturers, our patent portfolio, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2008, and other SEC filings from time to time.

SOURCE DUSA Pharmaceuticals, Inc.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
2. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
3. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
4. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
5. BioMarin Acquires Huxley Pharmaceuticals, Inc.
6. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
7. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
9. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
10. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
11. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):